Publications by authors named "Benoit Van Hille"
Article Synopsis
- Avelumab is a treatment approved for metastatic Merkel cell carcinoma (mMCC) and this study focused on its effectiveness in patients in France who received it as a second-line or later treatment.
- The study analyzed data from 180 patients, revealing a median overall survival of 14.6 months after starting avelumab and a 40.5% survival rate at 24 months.
- The results showed that real-world outcomes for avelumab align with previous clinical trial findings, reinforcing its recommendation as a standard treatment for mMCC.
Background: As healthcare management of highly active-relapsing-remitting multiple sclerosis (HA-RRMS) patients is more complex than for the whole multiple sclerosis (MS) population, this study assessed the related economic burden from a National Health Insurance's (NHI's) perspective.
Research Design And Methods: Study based on French NHI databases, using individual data on billing and reimbursement of outpatient and hospital healthcare consumption, paid sick leave and disability pension, over 2010-2017.
Results: Of the 9,596 HA-RRMS adult patients, data from 7,960 patients were analyzed with at least 2 years of follow-up.
Background: People with chronic diseases in France frequently incur out-of-pocket expenses (OOPE) related to their medical care.
Objective: The objective of this study was to evaluate OOPE incurred by people with multiple sclerosis (MS) with respect to direct non-medical and medical expenditure.
Methods: Data were collected through a web-based survey using an online patient community platform (Carenity).
Purpose: The purpose of the study was to investigate the mechanisms associated with antitumor activity and resistance to F11782, a novel dual catalytic inhibitor of topoisomerases with DNA repair-inhibitory properties.
Experimental Design: For that purpose, an F11782-resistant P388 leukemia subline (P388/F11782) has been developed in vivo and characterized.
Results: Weekly subtherapeutic doses of F11782 (10 mg/kg) induced complete resistance to F11782 after 8 weekly passages.